sorafenib has been researched along with epidermal growth factor in 17 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (epidermal growth factor) | Trials (epidermal growth factor) | Recent Studies (post-2010) (epidermal growth factor) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 24,155 | 217 | 4,699 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 13 (76.47) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Gettinger, S | 1 |
| Chan, P; Epstein, R; Poon, RT; Yau, T | 1 |
| Fujino, H; Kawashima, T; Kiuchi, Y; Matsumoto, I; Matsuzawa, Y; Murayama, T; Nakamura, H; Toyomura, K | 1 |
| Calvet, JP; Reif, GA; Wallace, DP; Yamaguchi, T | 1 |
| Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Koch, A | 1 |
| Lord, R; Ross, PJ; Suddle, A | 1 |
| Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J | 1 |
| Dufour, JF; Erös de Bethlenfalva-Hora, C; Geier, A; Kettenbach, J; Mertens, JC; Piguet, AC; Schmitt, J; Terracciano, L; Weimann, R | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Hayward, S; Iakovou, G; Laycock, SD | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R | 1 |
| Kim, D; Ko, HS; Park, GB | 1 |
| Clayton, SA; Lazzara, MJ; Myers, PJ; Sorkin, A; Surve, SV; Watkins, SC | 1 |
| Chen, J; Chen, X; Guo, Y; Hong, J; Li, J; Li, M; Liu, J; Ma, Q; Qi, Y; Qian, C; Shan, J; Shen, J; Wang, M; Wu, H; Xu, H; Xu, Y; Yang, Z; Yao, C; Zhang, Q; Zhao, W | 1 |
| Albandea-Rodríguez, D; Arconada-Luque, E; Belandia, B; Encinar, JA; Fernández-Aroca, DM; Muñoz, I; Ortega-Muelas, M; Pascual-Serra, R; Roche, O; Ruiz-Hidalgo, MJ; Sánchez-Pérez, I; Sánchez-Prieto, R | 1 |
3 review(s) available for sorafenib and epidermal growth factor
| Article | Year |
|---|---|
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Management of advanced hepatocellular carcinoma in the era of targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Drug Delivery Systems; Epidermal Growth Factor; Humans; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Signal Transduction; Sorafenib | 2009 |
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Epidermal Growth Factor; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
14 other study(ies) available for sorafenib and epidermal growth factor
| Article | Year |
|---|---|
Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
Topics: Benzenesulfonates; Cytosol; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Group IV Phospholipases A2; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; Temperature; Tetradecanoylphorbol Acetate; Time Factors | 2009 |
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Topics: Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; Humans; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Polycystic Kidney, Autosomal Dominant; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2010 |
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.
Topics: Alanine Transaminase; Animals; Benzenesulfonates; Catheter Ablation; Cell Proliferation; Epidermal Growth Factor; Fluorescent Antibody Technique; Glutamate Dehydrogenase; Hepatocyte Growth Factor; Image Processing, Computer-Assisted; Liver; Male; Models, Animal; Necrosis; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Hepatocyte Growth Factor; Interleukin-10; Liver Neoplasms, Experimental; Macrophages; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta; Vascular Endothelial Growth Factors | 2014 |
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2014 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
Adaptive GPU-accelerated force calculation for interactive rigid molecular docking using haptics.
Topics: Algorithms; Animals; Aprotinin; Benchmarking; Binding Sites; Cattle; Chaperonin 10; Chaperonin 60; Computer Graphics; Epidermal Growth Factor; ErbB Receptors; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins B-raf; Sorafenib; Trypsin; User-Computer Interface | 2015 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred NOD; Mice, SCID; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Sorafenib; Time Factors | 2017 |
Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Topics: Basigin; Cell Line, Tumor; Cell Movement; Down-Regulation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Hyaluronan Synthases; Hyaluronic Acid; MAP Kinase Signaling System; Neoplasm Invasiveness; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib | 2017 |
Localization dynamics of endogenous fluorescently labeled RAF1 in EGF-stimulated cells.
Topics: Cell Membrane; Endosomes; Epidermal Growth Factor; Fluorescence; HeLa Cells; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Staining and Labeling; Subcellular Fractions; Time Factors | 2019 |
KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Hep G2 Cells; Heterografts; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Phosphorylation; Sorafenib | 2019 |
ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology.
Topics: Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Movement; Disease Susceptibility; Epidermal Growth Factor; Flow Cytometry; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 7; Molecular Targeted Therapy; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Structure-Activity Relationship | 2021 |